Header Logo

Connection

Angela Woodiwiss to Pentoxifylline

This is a "connection" page, showing publications Angela Woodiwiss has written about Pentoxifylline.
Connection Strength

0,545
  1. Phosphodiesterase inhibition promotes the transition from compensated hypertrophy to cardiac dilatation in rats. Pflugers Arch. 2006 Jan; 451(4):526-33.
    View in: PubMed
    Score: 0,255
  2. Inotropic responses to phosphodiesterase inhibitors in cardiac hypertrophy in rats. Eur J Pharmacol. 2005 May 09; 514(2-3):201-8.
    View in: PubMed
    Score: 0,062
  3. A phosphodiesterase inhibitor promotes the premature development of adverse cardiac remodelling mediated by beta-adrenergic activation in hypertension. S Afr Med J. 2004 Oct; 94(10):833-4.
    View in: PubMed
    Score: 0,059
  4. C-reactive protein predicts response to pentoxifylline in patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2004 Oct; 6(6):731-4.
    View in: PubMed
    Score: 0,059
  5. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation. 2004 Feb 17; 109(6):750-5.
    View in: PubMed
    Score: 0,057
  6. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol. 2002 Nov 15; 90(10):1118-22.
    View in: PubMed
    Score: 0,052
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.